Log in

NASDAQ:PSNLPersonalis Stock Price, Forecast & News

$14.21
+0.58 (+4.26 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.52
Now: $14.21
$14.57
50-Day Range
$10.26
MA: $12.56
$14.21
52-Week Range
$4.27
Now: $14.21
$25.64
Volume258,411 shs
Average Volume372,626 shs
Market Capitalization$450.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers. The company also provides accuracy and content enhanced platform (ACE) that enhances nucleic acid preparation processes and combines it with patented assay and sequencing methods. ACE Platform offers multiple products and services, such as ACE extended cancer panel for DNA and RNA, and ACE cancer research Exome and Transcriptome. In addition, it develops NeXT Dx test, which helps oncologists to identify potential therapies and clinical trial options for cancer patients, as well as offers whole genome sequencing, which provides DNA sequencing and data analysis services; and ACE CancerPlus Test. The company also provides a liquid biopsy assay that analyzes various human genes versus the more narrowly focused liquid biopsy assays that are currently available. It serves approximately 50 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.15 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.21 million
Book Value$3.42 per share

Profitability

Net Income$-25,080,000.00

Miscellaneous

Employees181
Market Cap$450.60 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.

Personalis (NASDAQ:PSNL) Frequently Asked Questions

How has Personalis' stock been impacted by COVID-19 (Coronavirus)?

Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PSNL stock has increased by 136.0% and is now trading at $14.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Personalis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Personalis.

When is Personalis' next earnings date?

Personalis is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Personalis.

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.03. The business had revenue of $19.16 million for the quarter, compared to analyst estimates of $16.80 million. Personalis had a negative return on equity of 26.28% and a negative net margin of 40.60%. View Personalis' earnings history.

What price target have analysts set for PSNL?

5 Wall Street analysts have issued 12 month price objectives for Personalis' stock. Their forecasts range from $14.00 to $29.00. On average, they expect Personalis' stock price to reach $22.25 in the next year. This suggests a possible upside of 56.6% from the stock's current price. View analysts' price targets for Personalis.

Has Personalis been receiving favorable news coverage?

Media stories about PSNL stock have trended negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Personalis earned a news impact score of -2.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the next few days. View the latest news about Personalis.

Are investors shorting Personalis?

Personalis saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 895,500 shares, a drop of 15.5% from the May 31st total of 1,060,000 shares. Based on an average trading volume of 365,200 shares, the days-to-cover ratio is presently 2.5 days. Currently, 5.7% of the shares of the company are sold short. View Personalis' Current Options Chain.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Who are Personalis' key executives?

Personalis' management team includes the following people:
  • Mr. John Stephen West, Co-Founder, CEO, Pres & Director (Age 63, Pay $785.44k)
  • Mr. Aaron L. Tachibana, Chief Financial Officer (Age 59, Pay $494.4k)
  • Dr. Richard Chen M.S., M.D., MS, Chief Scientific Officer (Age 49, Pay $543.75k)
  • Prof. Russ B. Altman, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $14.21.

How big of a company is Personalis?

Personalis has a market capitalization of $450.60 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 181 workers across the globe.

What is Personalis' official website?

The official website for Personalis is www.personalis.com.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.